JP-2022512471-A5 -

Dates

Publication Date

20221220

Application Date

20191212

Description

Various modifications and alterations to embodiments of the present disclosure will be obvious to those skilled in the art. Such modifications and alterations (including, but not limited to, modifications and alterations to chemical structures, substituents, derivatives, intermediates, synthesis, compositions, formulations, or methods of use in the present invention) can be made without departing from the spirit and scope of the present disclosure. Another aspect of the present invention may be as follows: [1] Compound of formula (I): (I) or its salt (In the formula, A is selected from aryl, heteroaryl, and heterocyclyl compounds, each of which may optionally be substituted with one, two, or three substituents. R1 is a C6 - C20 alkyl group, R2 is selected from hydrogen and -COOH . n is either 1 or 2. [2] The compound described in [1] above, or a salt thereof, wherein A is phenyl, which is unsubstituted or substituted with one, two, three, or four substituents independently selected from C1 - C4 alkyl , C1 - C4 alkoxy , and halo. [3] The compound described in [ 1] above, or a salt thereof, wherein A is unsubstituted, or a five-membered or six-membered monocyclic heteroaryl compound substituted with one, two, or three substituents independently selected from C1 - C4 alkyl , C1 - C4 alkoxy, and halo. [4] The compound described in [1] above, or a salt thereof, wherein A is an unsubstituted bicyclic heterocyclyl group. [5] A is selected from 2,3-dihydrobenzofuranyl and chromanil, the compound described in [4] above, or a salt thereof. [6] A compound according to any one of the above items [1] to [5], wherein R1 is C8 - C14 alkyl. [7] The compound described in [6] above, or a salt thereof, wherein R1 is a C12 alkyl group . [8] A compound according to any one of the above items [1] to [7], wherein R2 is hydrogen, or a salt thereof. [9] A compound according to any one of the above items [1] to [7], wherein R 2 is -COOH, or a salt thereof. [10] A compound according to any one of the above items [1] to [9], or a salt thereof, wherein n is 1. [11] A compound according to any one of the above items [1] to [9], or a salt thereof, wherein n is 2. [12] The compound according to any one of the above items [1] to [11], wherein the compound takes the form of an alkali metal salt. [13] The compound is and A compound selected from the above [1]. [14] A composition comprising a compound described in any one of the above items [1] to [13] and a DNA polymerase. [15] The composition according to [14], wherein the DNA polymerase is a heat-stable DNA polymerase. [16] The composition according to [15], wherein the heat-stable DNA polymerase is selected from the group consisting of Taq, Tca, Tfu, Tbr, Tth, Tih, Tfi, Tli, Tfl, Pfu, Pwo, KOD, Tma, Tne, Bst, Pho, Sac, Sso, ES4, or variants, variants, or derivatives thereof. [17] The composition according to [14], wherein the compound is bound to the DNA polymerase. [18] The composition according to [17], wherein the compound inhibits the activity of the DNA polymerase. [19] The composition according to [14], further comprising one or more nucleic acid amplification reagents. [20] The composition according to [19], wherein one or more amplification reagents are selected from the group consisting of deoxynucleotide triphosphates, buffers, magnesium salts (e.g., MgCl2 or MgSO4 ) , oligonucleotide primers, and nucleic acid templates. [21] A composition comprising a compound described in any one of the above items [1] to [13] and one or more nucleic acid amplification reagents. [22] The composition according to [21], wherein one or more amplification reagents are selected from the group consisting of polymerase, deoxynucleotide triphosphate, buffer, magnesium salt (e.g., MgCl2 or MgSO4 ) , oligonucleotide primer, and nucleic acid template. [23] Compound of formula (II): (II) or its salt (In the formula, A is selected from monocyclic or bicyclic aryl, heteroaryl, or heterocyclyl groups, each of which may optionally be substituted with one, two, or three substituents. R1 is a C6 - C20 alkyl group, R2 is selected from hydrogen and -COOH . n is either 1 or 2, R3 is selected from -COOH and -SO3X ( wherein X is selected from hydrogen, alkali metal cations, and ammonium cations), One or more nucleic acid amplification reagents and A composition containing the following: [24] The composition according to [23], wherein A is phenyl, which is either unsubstituted or substituted with one, two, three, or four substituents independently selected from C1 - C4 alkyl, C1 - C4 alkoxy , and halo. [25] The composition according to [23], wherein A is unsubstituted or substituted with one, two, or three substituents independently selected from C1 - C4 alkyl , C1 - C4 alkoxy , and halo, a five-membered or six-membered monocyclic heteroaryl. [26] The composition according to [23], wherein A is an unsubstituted bicyclic heterocyclyl group. [27] The composition according to [26], wherein A is selected from 2,3-dihyd